Scientists Identify Gene Vital to Early Embryonic Cells Forming a Normal Heart and Skull
In a study posted online June 15, 2009 by the Proceedings of the National Academy of Sciences, a research team at Cincinnati Childrens reports that too little of the gene/protein SHP2 interferes with the normal developmental activity of what are called neural crest cells. These cells, which occur very early in embryonic development, migrate to specific regions of the embryo. While doing so, the cells are supposed to differentiate and give rise to certain nerve tissues, craniofacial bones or smooth muscle tissue of the heart.
Our findings show that a deficiency of SHP2 in neural crest cells results in a failure of cell differentiation at diverse sites in the developing embryo, said Jeffrey Robbins, PhD, co-director of the Heart Institute at Cincinnati Childrens and senior investigator of the study. This leads to anatomical and functional deficits so severe that it precludes viability of the developing fetus.
SHP2 is a tyrosine phosphatase an enzyme that helps trigger a cascade of biochemical reactions in cells as they specify to form certain tissues.
Although the study was conducted using mouse embryos, the findings are significant in efforts to understand congenital malformations of the heart and craniofacial region in people. Especially relevant, the researchers said, is the insight gained into early molecular events during embryonic development that might help explain such birth defects.
Robbins, professor of pediatrics at the
The study was supported by grants from the National Institutes of Health. Other researchers include first author, Tomoki Nakamura, along with James Gulick, and Melissa Colbert, all of the division of molecular cardiovascular biology at Cincinnati Childrens.
Tags
Related Stories
UC radiation oncologist speaks with Local 12 news about clinical trial for head and neck cancer treatment
August 10, 2026
Dr. Sara Medek, a UC radiation oncology professor, speaks with Local 12 news about a new clinical trial aimed at reducing radiation in certain areas while still treating cancer effectively but with fewer painful side effects.
Cancer Center director charts future based on collaboration, AI
August 10, 2026
David Gius, MD, PhD, was featured in a Cincinnati Business Courier article and The Cancer Letter’s “The Directors" podcast discussing his priorities and goals as he recently took the helm as director of the University of Cincinnati Cancer Center.
Bidirectional link between oral, kidney health calls for patient education, access
August 4, 2026
Despite growing awareness of the connection between oral health and chronic health conditions, patient awareness and access to dental care remain limited, according to University of Cincinnati experts who recently spoke with Healio | Nephrology News & Issues.